Inês Cordeiro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Inês Cordeiro has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
A. Cordeiro
Rheumatology, Hospital Garcia de Orta, Almada, Portugal
2 shared publicationsAdriano Neto
2 shared publications- Alexandre Sepriano
NOVA Medical School, Universidade NOVA de Lisboa, Lisbon, Portugal; Department of Rheumatology, Hospital de Egas Moniz-ULSLO, Lisbon, Portugal
2 shared publications - Catarina Ambrosio
Ctr Hosp Baixo Vouga, Rheumatol Dept, Epe Aveiro, Portugal
2 shared publications Filipa Teixeira
2 shared publications- Helena Canhão
EpiDoc Unit, NOVA Medical School, Comprehensive Health Research Center (CHRC), Universidade NOVA de Lisboa, Lisboa, Portugal
2 shared publications
Latest Publications
- 1 June 2016
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 75 (Suppl 2) , 104-105
OP0129 Nailfold Capillaroscopy in Rheumatology Practice - A Single Center Experience
Background Nailfold capillaroscopy (NCP) is an easy, non-invasive and useful tool for the diagnosis and follow-up of Systemic Sclerosis (SSc) and other systemic rheumatic diseases. Objectives To present our single center experience with NCP, describing the main reasons for NCP request, and the major abnormalities detected in capillaroscopy. Methods Retrospective analysis of patients submitted to NCP assessment, from January 2013 to December 2015 in our center. We collected reasons for NCP request, demographic and clinical data, autoimmunity profile and NCP results. Results A total of 221 NPC, corresponding to 197 patients, 167 females (84.8%) and 30 males (15.2%) aged from 9 to 90 years were reviewed. One hundred and thirty eight (62.4%) patients had no definitive diagnosis, 53 patients (24%) had SSc, 7 (3.2%) had mixed connective tissue disease, 3 (1.4%) had dermatomyositis/polymyositis (DM/PM), and 3 (1.4%) antiphospholipid syndrome (APS). Raynaud's phenomenon (RP) alone was the most frequent reason for requesting NCP (33% of the cases), and combined with ANA positivity accounted for another 30.8% of the requests. RP was present in 73.3% of the patients, acrocyanosis in 16.3%, livedo reticularis and puffy hands accounted for 8.6% each one. Anti-nuclear antibodies (ANA) were positive in 59.7%, anti-centromere antibodies were present in 21.3%, anti-topoisomerase I and SSA/SSB in 5.1% of the cases. One hundred and fifty nine (71.9%) NCP were considered abnormal. The most frequent specific disease pattern was the early one (Cuttolo) in 15%. The most frequent findings were: capillary tortuosity in 112 (71.8%) cases, capillary dilatations in 95 (60.9%), and hemorrhages in 85 (54.5%). NCP was abnormal in 79.4% of patients with RP and ANA, 41.2% of them displaying specific findings of rheumatic diseases (Table 1). In SSc patients the late and the early pattern (Cuttolo) were the most frequent, present in 15 and 13 NCP, respectively. Concerning specific NCP findings capillary dilatations (81%), hemorrhages (73.6%) and megacapillaries (71.7%) were the most frequent (Table 2). Of the 138 cases without definitive diagnosis, 61. 6% had abnormal NCP, although mostly with non-specific patterns (50%). In 10 (7.2%) patients NCP helped to establish the diagnosis: VEDOSS (Very Early Diagnosis of Systemic Sclerosis) in 6, antiphospholipid syndrome in 3 and DM in one case. Conclusions In our experience, NCP was helpful for the diagnosis of rheumatic systemic disease. Specific NCP findings were more frequent in patients with RP + ANA positivity, suggesting that this combination is associated with more disease incidence. Patients with isolated RF had less pathologic NCP findings than those with isolated. ANA positivity. The prospective follow up of those patients with abnormal NCP and no definitive diagnosis will help to establish the predictive value of observed alterations. Cutolo M, Pizzorni C, Sulli A. Capillaroscopy. Best Pract Res Clin Rheumatol. 2005 Jun;19(3):437–52 Disclosure of Interest None declared
- 1 June 2016
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 75 (Suppl 2) , 104-105
OP0129 Nailfold Capillaroscopy in Rheumatology Practice - A Single Center Experience
Background Nailfold capillaroscopy (NCP) is an easy, non-invasive and useful tool for the diagnosis and follow-up of Systemic Sclerosis (SSc) and other systemic rheumatic diseases. Objectives To present our single center experience with NCP, describing the main reasons for NCP request, and the major abnormalities detected in capillaroscopy. Methods Retrospective analysis of patients submitted to NCP assessment, from January 2013 to December 2015 in our center. We collected reasons for NCP request, demographic and clinical data, autoimmunity profile and NCP results. Results A total of 221 NPC, corresponding to 197 patients, 167 females (84.8%) and 30 males (15.2%) aged from 9 to 90 years were reviewed. One hundred and thirty eight (62.4%) patients had no definitive diagnosis, 53 patients (24%) had SSc, 7 (3.2%) had mixed connective tissue disease, 3 (1.4%) had dermatomyositis/polymyositis (DM/PM), and 3 (1.4%) antiphospholipid syndrome (APS). Raynaud's phenomenon (RP) alone was the most frequent reason for requesting NCP (33% of the cases), and combined with ANA positivity accounted for another 30.8% of the requests. RP was present in 73.3% of the patients, acrocyanosis in 16.3%, livedo reticularis and puffy hands accounted for 8.6% each one. Anti-nuclear antibodies (ANA) were positive in 59.7%, anti-centromere antibodies were present in 21.3%, anti-topoisomerase I and SSA/SSB in 5.1% of the cases. One hundred and fifty nine (71.9%) NCP were considered abnormal. The most frequent specific disease pattern was the early one (Cuttolo) in 15%. The most frequent findings were: capillary tortuosity in 112 (71.8%) cases, capillary dilatations in 95 (60.9%), and hemorrhages in 85 (54.5%). NCP was abnormal in 79.4% of patients with RP and ANA, 41.2% of them displaying specific findings of rheumatic diseases (Table 1). In SSc patients the late and the early pattern (Cuttolo) were the most frequent, present in 15 and 13 NCP, respectively. Concerning specific NCP findings capillary dilatations (81%), hemorrhages (73.6%) and megacapillaries (71.7%) were the most frequent (Table 2). Of the 138 cases without definitive diagnosis, 61. 6% had abnormal NCP, although mostly with non-specific patterns (50%). In 10 (7.2%) patients NCP helped to establish the diagnosis: VEDOSS (Very Early Diagnosis of Systemic Sclerosis) in 6, antiphospholipid syndrome in 3 and DM in one case. Conclusions In our experience, NCP was helpful for the diagnosis of rheumatic systemic disease. Specific NCP findings were more frequent in patients with RP + ANA positivity, suggesting that this combination is associated with more disease incidence. Patients with isolated RF had less pathologic NCP findings than those with isolated. ANA positivity. The prospective follow up of those patients with abnormal NCP and no definitive diagnosis will help to establish the predictive value of observed alterations. Cutolo M, Pizzorni C, Sulli A. Capillaroscopy. Best Pract Res Clin Rheumatol. 2005 Jun;19(3):437–52 Disclosure of Interest None declared
- 1 June 2016
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 75 (Suppl 2) , 754
SAT0237 Nailfold Capillaroscopy Findings in Scleroderma Patients – Prognostic Implications
Background Nailfold capillaroscopy (NCP) is a useful tool for the diagnosis and follow-up of systemic rheumatic diseases and represents one of the best methods to evaluate microvascular abnormalities. Objectives To characterize NCP findings of patients with Systemic Sclerosis (SSc), and understand how NCP associates with the presence of digital ulcers, gastrointestinal involvement, pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD). Methods NCP findings of adult patients with SSc followed-up in our center were reviewed. Demographic and clinical features were collected. Nonparametric tests were used to determine potential associations between capillaroscopy findings/patterns and the presence of digital ulcers, gastrointestinal involvement, PAH and ILD. Results In total, 52 out of 103 patients with SSc had at least one NCP result available. Forty five were female (86.5%) and seven male (13.5%), the age was 56.6 ±13.2 years and disease duration 10.9 ±10.5 years. Thirty one (59.6%) had limited cutaneous SSc, seven (13.5%) diffuse cutaneous SSc, ten (19,2%) VEDOSS, three (5.8%) overlap syndromes and one (1.9%) SSc sine scleroderma. (table 1). The most frequent NCP findings were hemorrhages (54.7%) megacapillaries (54.7%), and capillary dilatations (52.8%). We found that digital ulcers were significantly associated with the existence of avascular areas (p=0.02), and with neoangiogenesis (p=0.03) in univariate analysis, but were not associated with any capillaroscopy pattern. Looking to interstitial lung disease, there is a trend for association with the presence of avascular areas (p=0.056). Only one patient had PAH confirmed by right heart catheterization. In this case NCP showed giant capillaries, neoangiogenesis and avascular areas. There was also a trend for association between avascular areas and higher values of NT pro BNP (p=0.078). Gastrointestinal involvement was not significantly associated with NCP findings (table 2). Distribution of patients according to NCP and disease subtypes Conclusions In our study the presence of avascular areas and neoangiogenesis in NCP was significantly associated with the existence of digital ulcers. Also, ILD and higher values of NT-proBNP were more common in patients who present avascular areas. These results suggest that abnormalities detected in the NCP might help predict organ involvement, although long term follow up and greater numbers of patients are needed in order to confirm the prognostic value of NCP findings. Mannarino E, Pasqualini L, Fedeli F, Scricciolo V, Innocente S. Nailfold capillaroscopy in the screening and diagnosis of Raynaud's phenomenon. Angiology 1994; 45: 37–42 Disclosure of Interest None declared
- 1 June 2016
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 75 (Suppl 2) , 754
SAT0237 Nailfold Capillaroscopy Findings in Scleroderma Patients – Prognostic Implications
Background Nailfold capillaroscopy (NCP) is a useful tool for the diagnosis and follow-up of systemic rheumatic diseases and represents one of the best methods to evaluate microvascular abnormalities. Objectives To characterize NCP findings of patients with Systemic Sclerosis (SSc), and understand how NCP associates with the presence of digital ulcers, gastrointestinal involvement, pulmonary arterial hypertension (PAH) and interstitial lung disease (ILD). Methods NCP findings of adult patients with SSc followed-up in our center were reviewed. Demographic and clinical features were collected. Nonparametric tests were used to determine potential associations between capillaroscopy findings/patterns and the presence of digital ulcers, gastrointestinal involvement, PAH and ILD. Results In total, 52 out of 103 patients with SSc had at least one NCP result available. Forty five were female (86.5%) and seven male (13.5%), the age was 56.6 ±13.2 years and disease duration 10.9 ±10.5 years. Thirty one (59.6%) had limited cutaneous SSc, seven (13.5%) diffuse cutaneous SSc, ten (19,2%) VEDOSS, three (5.8%) overlap syndromes and one (1.9%) SSc sine scleroderma. (table 1). The most frequent NCP findings were hemorrhages (54.7%) megacapillaries (54.7%), and capillary dilatations (52.8%). We found that digital ulcers were significantly associated with the existence of avascular areas (p=0.02), and with neoangiogenesis (p=0.03) in univariate analysis, but were not associated with any capillaroscopy pattern. Looking to interstitial lung disease, there is a trend for association with the presence of avascular areas (p=0.056). Only one patient had PAH confirmed by right heart catheterization. In this case NCP showed giant capillaries, neoangiogenesis and avascular areas. There was also a trend for association between avascular areas and higher values of NT pro BNP (p=0.078). Gastrointestinal involvement was not significantly associated with NCP findings (table 2). Distribution of patients according to NCP and disease subtypes Conclusions In our study the presence of avascular areas and neoangiogenesis in NCP was significantly associated with the existence of digital ulcers. Also, ILD and higher values of NT-proBNP were more common in patients who present avascular areas. These results suggest that abnormalities detected in the NCP might help predict organ involvement, although long term follow up and greater numbers of patients are needed in order to confirm the prognostic value of NCP findings. Mannarino E, Pasqualini L, Fedeli F, Scricciolo V, Innocente S. Nailfold capillaroscopy in the screening and diagnosis of Raynaud's phenomenon. Angiology 1994; 45: 37–42 Disclosure of Interest None declared
- 9 May 2014
- Vol. 39 (1) , 19-26
Pharmacology of biosimilar candidate drugs in rheumatology: a literature review.
To review current evidence concerning pharmacology of biosimilar candidates to be used in rheumatology. A PubMed search up to August 2013 was performed using relevant search terms to include all studies assessing pharmacological properties of biosimilar candidates to be used in rheumatology. Data on study characteristics, type of intervention, pharmacokinetics (PK), pharmacodynamics (PD) and bioequivalence ratios was extracted. Of 280 articles screened, 5 fulfilled our inclusion criteria. Two trials, PLANETAS and PLANETRA, compared CT-P13 and infliximab in patients with active ankylosing spondylitis and rheumatoid arthritis, respectively. PK bioequivalence was demonstrated in the phase 1 PLANETAS trial by highly comparable area under the curve (AUC) and maximum drug concentrations (Cmax), whose geometric mean ratios fell between the accepted bioequivalence range of 80-125%. Equivalence in efficacy and safety was demonstrated in the phase 3 PLANETRA trial. Two phase 1 trials comparing etanercept biosimilar candidates TuNEX and HD203 in healthy volunteers showed a high degree of similarity in AUC and Cmax, with respective geometric mean ratios between PK bioequivalence range. The last included trial referred to GP2013, a rituximab biosimilar candidate, which demonstrated PK and PD bioequivalence to reference product in three different dosing regimens in cynomolgus monkeys. Infliximab, etanercept and rituximab biosimilar candidates have demonstrated PK bioequivalence in the trials included in this review. CT-P13 has recently been approved for use in the European market and the remaining biosimilar candidates are currently being tested in patients with rheumatoid arthritis.
- 9 May 2014
- Vol. 39 (1) , 19-26
Pharmacology of biosimilar candidate drugs in rheumatology: a literature review.
To review current evidence concerning pharmacology of biosimilar candidates to be used in rheumatology. A PubMed search up to August 2013 was performed using relevant search terms to include all studies assessing pharmacological properties of biosimilar candidates to be used in rheumatology. Data on study characteristics, type of intervention, pharmacokinetics (PK), pharmacodynamics (PD) and bioequivalence ratios was extracted. Of 280 articles screened, 5 fulfilled our inclusion criteria. Two trials, PLANETAS and PLANETRA, compared CT-P13 and infliximab in patients with active ankylosing spondylitis and rheumatoid arthritis, respectively. PK bioequivalence was demonstrated in the phase 1 PLANETAS trial by highly comparable area under the curve (AUC) and maximum drug concentrations (Cmax), whose geometric mean ratios fell between the accepted bioequivalence range of 80-125%. Equivalence in efficacy and safety was demonstrated in the phase 3 PLANETRA trial. Two phase 1 trials comparing etanercept biosimilar candidates TuNEX and HD203 in healthy volunteers showed a high degree of similarity in AUC and Cmax, with respective geometric mean ratios between PK bioequivalence range. The last included trial referred to GP2013, a rituximab biosimilar candidate, which demonstrated PK and PD bioequivalence to reference product in three different dosing regimens in cynomolgus monkeys. Infliximab, etanercept and rituximab biosimilar candidates have demonstrated PK bioequivalence in the trials included in this review. CT-P13 has recently been approved for use in the European market and the remaining biosimilar candidates are currently being tested in patients with rheumatoid arthritis.
- 9 May 2014
- Vol. 39 (1) , 60-71
The Portuguese Society of Rheumatology position paper on the use of biosimilars.
Biotechnological drugs have become a fundamental resource for the treatment of rheumatic patients. Patent expiry of some of these drugs created the opportunity for biopharmaceutical manufacturers to develop biosimilar drugs intended to be as efficacious as the originator product but with a lower cost to healthcare systems. Due to the complex manufacturing process and highly intricate structure of biologicals, a biosimilar can never be an exact copy of its reference product. Consequently, regulatory authorities issued strict preclinical and clinical guidelines to ensure safety and efficacy equivalence and, in September 2013, the biosimilar of infliximab was the first biosimilar monoclonal antibody to be authorized for use in the European Union. The current document is a position statement of the "Sociedade Portuguesa de Reumatologia" (Portuguese Society of Rheumatology) on the use of biosimilar drugs in rheumatic diseases. Two systematic literature reviews were performed, one concerning clinical trials and the other one concerning international position papers on biosimilars. The results were presented and discussed in a national meeting and a final position document was discussed, written and approved by Portuguese rheumatologists. Briefly, this position statement is contrary to automatic substitution of the originator by the biosimilar, defends either a different INN or the prescription by brand name, supports that switching between biosimilars and the originator molecule should be done after at least 6 months of treatment and based on the attending physician decision and after adequate patient information, recommends the registration of all biosimilar treated patients in Reuma.pt for efficacy, safety and immunogenicity surveillance, following the strategy already ongoing for originators, and opposes to extrapolation of indications approved to the originator to completely different diseases and/or age groups without adequate pre-clinical, safety or efficacy data.
- 9 May 2014
- Vol. 39 (1) , 60-71
The Portuguese Society of Rheumatology position paper on the use of biosimilars.
Biotechnological drugs have become a fundamental resource for the treatment of rheumatic patients. Patent expiry of some of these drugs created the opportunity for biopharmaceutical manufacturers to develop biosimilar drugs intended to be as efficacious as the originator product but with a lower cost to healthcare systems. Due to the complex manufacturing process and highly intricate structure of biologicals, a biosimilar can never be an exact copy of its reference product. Consequently, regulatory authorities issued strict preclinical and clinical guidelines to ensure safety and efficacy equivalence and, in September 2013, the biosimilar of infliximab was the first biosimilar monoclonal antibody to be authorized for use in the European Union. The current document is a position statement of the "Sociedade Portuguesa de Reumatologia" (Portuguese Society of Rheumatology) on the use of biosimilar drugs in rheumatic diseases. Two systematic literature reviews were performed, one concerning clinical trials and the other one concerning international position papers on biosimilars. The results were presented and discussed in a national meeting and a final position document was discussed, written and approved by Portuguese rheumatologists. Briefly, this position statement is contrary to automatic substitution of the originator by the biosimilar, defends either a different INN or the prescription by brand name, supports that switching between biosimilars and the originator molecule should be done after at least 6 months of treatment and based on the attending physician decision and after adequate patient information, recommends the registration of all biosimilar treated patients in Reuma.pt for efficacy, safety and immunogenicity surveillance, following the strategy already ongoing for originators, and opposes to extrapolation of indications approved to the originator to completely different diseases and/or age groups without adequate pre-clinical, safety or efficacy data.
- 1 April 2014
- Vol. 39 (2) , 158-171
Portuguese recommendations for the diagnosis and management of Gout
Objective: To develop Portuguese evidence-based recommendations for the Diagnosis and Management of Gout. Methods: As part of the 3e Initiative (Evidence, Expertise and Exchange), a panel of 78 international rheumatologists developed 10 relevant clinical questions which were investigated with systematic literature reviews. MEDLINE, EMBASE, Cochrane CENTRAL and abstracts from 2010-2011 EULAR and ACR meetings were searched. Based on the evidence found in the published literature, rheumatologists from 14 countries developed national recommendations that were merged and voted into multinational recommendations. We present the Portuguese recommendations for the Diagnosis and Management of Gout which were formulated and voted by Delphi method in April 2012, in Lisbon. The level of agreement and potential impact in clinical practice was also assessed. Results: Twelve national recommendations were elaborated from 10 international and 2 national questions. These recommendations addressed the diagnosis of gout; the treatment of acute flares and urate-lowering therapy; monitoring of gout and comorbidity screening; the influence of comorbidities in drug choice; lifestyle; flare prophylaxis; management of tophi and asymptomatic hyperuricaemia; the role of urine alkalinization; and the burden of gout. The level of agreement with the recommendations ranged from 6.8 to 9.0 (mean 7.7) on a 1-10 point visual analogue scale, in which 10 stands for full agreement. Conclusion: The 12 Portuguese recommendations for the Diagnosis and Management of Gout were formulated according to the best evidence and endorsed by a panel of 42 rheumatologists, enhancing their validity and practical use in daily clinical practice.
- 1 April 2014
- Vol. 39 (2) , 158-171
Portuguese recommendations for the diagnosis and management of Gout
Objective: To develop Portuguese evidence-based recommendations for the Diagnosis and Management of Gout. Methods: As part of the 3e Initiative (Evidence, Expertise and Exchange), a panel of 78 international rheumatologists developed 10 relevant clinical questions which were investigated with systematic literature reviews. MEDLINE, EMBASE, Cochrane CENTRAL and abstracts from 2010-2011 EULAR and ACR meetings were searched. Based on the evidence found in the published literature, rheumatologists from 14 countries developed national recommendations that were merged and voted into multinational recommendations. We present the Portuguese recommendations for the Diagnosis and Management of Gout which were formulated and voted by Delphi method in April 2012, in Lisbon. The level of agreement and potential impact in clinical practice was also assessed. Results: Twelve national recommendations were elaborated from 10 international and 2 national questions. These recommendations addressed the diagnosis of gout; the treatment of acute flares and urate-lowering therapy; monitoring of gout and comorbidity screening; the influence of comorbidities in drug choice; lifestyle; flare prophylaxis; management of tophi and asymptomatic hyperuricaemia; the role of urine alkalinization; and the burden of gout. The level of agreement with the recommendations ranged from 6.8 to 9.0 (mean 7.7) on a 1-10 point visual analogue scale, in which 10 stands for full agreement. Conclusion: The 12 Portuguese recommendations for the Diagnosis and Management of Gout were formulated according to the best evidence and endorsed by a panel of 42 rheumatologists, enhancing their validity and practical use in daily clinical practice.
- 15 November 2012
- Vol. 37 (2) , 175-9
[Rheumatic expression of secondary syphilis].
Syphilis is a disease caused by Treponema pallidum infection with protean clinical manifestations. Musculoskeletal complaints are however uncommon and most of the time mild. Occasionally they can dominate the clinical picture and simulate a variety of rheumatic diseases. The authors present the clinical case of a 33-year-old woman who developed a lupus-like syndrome in the postpartum, characterized by polyarthritis, elevated acute phase reactants and positive antinuclear antibodies (ANA). Physical examination revealed a macular non-pruriginous skin rash involving the trunk, upper limbs and palms. The Rapid Plasma Reagin (RPR) and Treponema Pallidum Hemaglutination (TPHA) tests gave a positive result and the patient was diagnosed as secondary syphilis and medicated with 2.4 MU of benzathine penicillin intramuscular weekly for 3 weeks, with complete resolution of clinical signs and ANA negativation. The association of rash and arthritis may occur in several rheumatic diseases but in the presence of palmoplantar involvement, the possibility of syphilis infection should not be overlooked.
- 15 November 2012
- Vol. 37 (2) , 175-9
[Rheumatic expression of secondary syphilis].
Syphilis is a disease caused by Treponema pallidum infection with protean clinical manifestations. Musculoskeletal complaints are however uncommon and most of the time mild. Occasionally they can dominate the clinical picture and simulate a variety of rheumatic diseases. The authors present the clinical case of a 33-year-old woman who developed a lupus-like syndrome in the postpartum, characterized by polyarthritis, elevated acute phase reactants and positive antinuclear antibodies (ANA). Physical examination revealed a macular non-pruriginous skin rash involving the trunk, upper limbs and palms. The Rapid Plasma Reagin (RPR) and Treponema Pallidum Hemaglutination (TPHA) tests gave a positive result and the patient was diagnosed as secondary syphilis and medicated with 2.4 MU of benzathine penicillin intramuscular weekly for 3 weeks, with complete resolution of clinical signs and ANA negativation. The association of rash and arthritis may occur in several rheumatic diseases but in the presence of palmoplantar involvement, the possibility of syphilis infection should not be overlooked.
- 1 January 2012
- Vol. 37 (1) , 26-39
2011 Portuguese recommendations for the use of biological therapies in patients with psoriatic arthritis
Objective: To develop recommendations for the treatment of psoriatic arthritis (PsA) with biological therapies, endorsed by the Portuguese Society of Rheumatology. Methods: These treatment recommendations were formulated by Portuguese rheumatologists based on literature evidence and consensus opinion. A draft of the recommendations was first circulated to all Portuguese rheumatologists and their suggestions were incorporated in the draft. At a national meeting the recommendations were discussed and all attending rheumatologists voted on the level of agreement for each recommendation. A second draft was again circulated before publication. Results: A consensus was achieved regarding the initiation, assessment of response and switching biological therapies in patients with PsA. Specific recommendations were developed for several disease domains: peripheral arthritis, axial disease, enthesitis and dactylitis. Conclusion: These recommendations may be used for guidance in deciding which patients with PsA should be treated with biological therapies. They cover a rapidly evolving area of therapeutic intervention. As more evidence becomes available and more biological therapies are licensed, these recommendations will have to be updated.
- 1 January 2012
- Vol. 37 (1) , 26-39
2011 Portuguese recommendations for the use of biological therapies in patients with psoriatic arthritis
Objective: To develop recommendations for the treatment of psoriatic arthritis (PsA) with biological therapies, endorsed by the Portuguese Society of Rheumatology. Methods: These treatment recommendations were formulated by Portuguese rheumatologists based on literature evidence and consensus opinion. A draft of the recommendations was first circulated to all Portuguese rheumatologists and their suggestions were incorporated in the draft. At a national meeting the recommendations were discussed and all attending rheumatologists voted on the level of agreement for each recommendation. A second draft was again circulated before publication. Results: A consensus was achieved regarding the initiation, assessment of response and switching biological therapies in patients with PsA. Specific recommendations were developed for several disease domains: peripheral arthritis, axial disease, enthesitis and dactylitis. Conclusion: These recommendations may be used for guidance in deciding which patients with PsA should be treated with biological therapies. They cover a rapidly evolving area of therapeutic intervention. As more evidence becomes available and more biological therapies are licensed, these recommendations will have to be updated.